ASBMR 2014

September 2014 - Entera presents the "First in Man Studies of Pharmacokinetic Profiles of Novel Oral Parathyroide Hormone PTH (1-34) Delivery System" for its osteoporosis drug at the annual meeting of ASBMR (The American Society of Bone and Mineral Research) in Houston, Texas. PK profiles showed that a single oral dose of PTH(1-34) is rapidly absorbed, and there is no significant difference in Cmax and Tmax when compared with the commercial injection. A transient increase in plasma cAMP was seen in all subjects in response to PTH (1-34) treatments. Increases in cAMP is indicative of PTH bio-activity, suggesting that the administered peptide is pharmacologically active and not degraded during GI transport.

pdfSee poster